Jacob Van Naarden, Senior VP, CEO of Loxo Oncology at Lilly; President, Lilly Oncology

Eli Lil­ly bags FDA nod for Verzenio in ear­ly breast can­cer, but a con­tro­ver­sial di­ag­nos­tic could dog its roll­out

As Eli Lil­ly works to con­sol­i­date its in­ter­nal and Loxo teams in­to an on­col­o­gy pow­er­house, the drug gi­ant is putting high hopes on CDK 4/6 in­hibitor Verzenio to help dri­ve the port­fo­lio in­to the fu­ture. Now, the drug has scored a par­a­digm-al­ter­ing win in ear­ly breast can­cer — but will a con­tro­ver­sial com­pan­ion di­ag­nos­tic ham­string Lil­ly’s mar­ket plans?

The FDA on Wednes­day ap­proved CDK 4/6 in­hibitor Verzenio in com­bi­na­tion with physi­cian’s-choice en­docrine ther­a­py to cut the risk of re­lapse in pa­tients with high-risk HR-pos­i­tive, HER2-neg­a­tive breast can­cer, Lil­ly said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA